AU2022325803A1 - Methods and compositions for treating fibrotic liver conditions, using udenafil compositions - Google Patents

Methods and compositions for treating fibrotic liver conditions, using udenafil compositions Download PDF

Info

Publication number
AU2022325803A1
AU2022325803A1 AU2022325803A AU2022325803A AU2022325803A1 AU 2022325803 A1 AU2022325803 A1 AU 2022325803A1 AU 2022325803 A AU2022325803 A AU 2022325803A AU 2022325803 A AU2022325803 A AU 2022325803A AU 2022325803 A1 AU2022325803 A1 AU 2022325803A1
Authority
AU
Australia
Prior art keywords
liver
patient
fibrotic
elf
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022325803A
Other languages
English (en)
Inventor
David J. GOLDBERG
Mark W. RUSSELL
Kurt R. SCHUMACHER
James L. Yeager
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mezzion Pharma Co Ltd
Original Assignee
Mezzion Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mezzion Pharma Co Ltd filed Critical Mezzion Pharma Co Ltd
Publication of AU2022325803A1 publication Critical patent/AU2022325803A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2022325803A 2021-08-13 2022-08-12 Methods and compositions for treating fibrotic liver conditions, using udenafil compositions Pending AU2022325803A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163233133P 2021-08-13 2021-08-13
US63/233,133 2021-08-13
PCT/US2022/040227 WO2023018972A1 (en) 2021-08-13 2022-08-12 Methods and compositions for treating fibrotic liver conditions, using udenafil compositions

Publications (1)

Publication Number Publication Date
AU2022325803A1 true AU2022325803A1 (en) 2024-03-28

Family

ID=83355014

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022325803A Pending AU2022325803A1 (en) 2021-08-13 2022-08-12 Methods and compositions for treating fibrotic liver conditions, using udenafil compositions

Country Status (7)

Country Link
US (2) US20230218622A1 (https=)
EP (1) EP4384176A1 (https=)
JP (1) JP2024532957A (https=)
AU (1) AU2022325803A1 (https=)
CA (1) CA3229274A1 (https=)
MX (1) MX2024001972A (https=)
WO (1) WO2023018972A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12396708B2 (en) * 2024-01-08 2025-08-26 Echosens Sa Method for determining an index for assessing a cardiac function of a subject
EP4582017A1 (en) * 2024-01-08 2025-07-09 Echosens Method for determining an index for assessing a cardiac function of a subject

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
PT1888074E (pt) * 2005-06-10 2012-03-01 Dong A Pharm Co Ltd Agente para a prevenção e tratamento de doenças do fígado contendo um derivado de pirazolopirimidina
TN2017000029A1 (en) 2014-08-12 2018-07-04 Mezzion Pharma Co Ltd Methods of improving myocardial performance in fontan patients using udenafil compositions

Also Published As

Publication number Publication date
EP4384176A1 (en) 2024-06-19
WO2023018972A1 (en) 2023-02-16
US20250186448A1 (en) 2025-06-12
US20230218622A1 (en) 2023-07-13
CA3229274A1 (en) 2023-02-16
JP2024532957A (ja) 2024-09-10
MX2024001972A (es) 2024-11-08

Similar Documents

Publication Publication Date Title
US20250186448A1 (en) Formulations of udenafil
JP2024020187A (ja) ウデナフィル組成物を用いてフォンタン患者における心筋性能を改善する方法
JP2025118624A (ja) ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法
US20240285630A1 (en) Methods and compositions for improving exercise performance
Goldberg et al. Results of the Fontan Udenafil exercise longitudinal (FUEL) trial
Patel et al. 2839 Dilated cardiomyopathy as the first presentation of coeliac disease: rare association or causation?